Previous 10 | Next 10 |
If you know what penny stocks are, you understand how risk plays a role. But you can’t expect uncapped gain potential from safe investments. The beauty of buying penny stocks, is having the ability to leverage less capital in exchange for a much larger gain percentage. Defined as...
Contrafect (CFRX): Q4 GAAP EPS of -$0.23 beats by $0.08.Cash, cash equivalents and marketable securities of $42.5MPress Release For further details see: Contrafect EPS beats by $0.08
Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021 Biomedical Advanced Research and Development Authority (BARDA) contract award provides up to $86.8 million f...
YONKERS, N.Y., March 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the closing of an underwritten...
Gainers: Moxian (MOXC) +92%.Jiayin Group (JFIN) +82%.Upstart (UPST) +78%.Dunxin Financial (DXF) +62%.Evolving Systems (EVOL) +28%.China Finance Online (JRJC) +25%.Hallmark Financial Services (HALL) +25%.Express (EXPR) +24%.Takung Art (TKAT) +23%.Luokung Technology (LKCO) +23%.L...
Gainers: Neos Therapeutics (NEOS) +17%,Aytu BioScience (AYTU) +14%, Vericel (VCEL) +14%, Brickell Biotech (BBI) +14%, Infinity Pharmaceuticals (INFI) +13%.Losers: Translate Bio (TBIO) -32%, ContraFect (CFRX) -13%, Lipocine (LPCN...
Translate Bio (TBIO) -26% after Translate Bio’s Cystic Fibrosis therapy fails to improve lung function in Phase 1/2 trial.PhaseBio Pharmaceuticals (PHAS) -14% on equity raise.Broadway Financial (BYFC) -13% after stockholders of Broadway Financial and CFBan...
ContraFect (CFRX) prices offering of 10M shares of common stock at $5.00/share, for gross proceeds of $50M.Underwriters' option to purchase up to an additional 1.5M shares.The offering to close on March 22, 2021.Shares down 14.5% pre-market.Previously (March 17): ContraFect und...
YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritte...
ContraFect (CFRX) trades 8.4% down after hours on commencing an underwritten public offering of shares; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer actual size, terms have not yet been disclosed.Net proceeds to be used for funding the c...
News, Short Squeeze, Breakout and More Instantly...
ContraFect Corporation Company Name:
CFRX Stock Symbol:
NASDAQ Market:
ContraFect Corporation Website:
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
ContraFect Corporation (CFRX) is expected to report $-0.66 for Q3 2023